GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (NSE:STAR) » Definitions » Forward PE Ratio

Strides Pharma Science (NSE:STAR) Forward PE Ratio : 12.02 (As of May. 03, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Strides Pharma Science Forward PE Ratio?

Strides Pharma Science's Forward PE Ratio for today is 12.02.

Strides Pharma Science's PE Ratio without NRI for today is 22.89.

Strides Pharma Science's PE Ratio (TTM) for today is 22.24.


Strides Pharma Science Forward PE Ratio Historical Data

The historical data trend for Strides Pharma Science's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Forward PE Ratio Chart

Strides Pharma Science Annual Data
Trend 2018-03
Forward PE Ratio
13.04

Strides Pharma Science Quarterly Data
2018-03 2018-06 2018-09 2024-12
Forward PE Ratio 13.04 7.48 9.62 12.68

Competitive Comparison of Strides Pharma Science's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Forward PE Ratio falls into.


;
;

Strides Pharma Science Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Strides Pharma Science  (NSE:STAR) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Strides Pharma Science Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Strides Pharma Science Business Description

Traded in Other Exchanges
Address
Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines